Navigation Links
Cellular target may prove useful in treating deadly brain tumors
Date:4/3/2009

DURHAM, N.C. Duke University researchers have identified a receptor on the surface of cells that may give them another avenue of attack against glioblastoma, the most common and most deadly type of brain cancer.

The neurokinin 1 receptor (NK1R), which may be expressed in all human glioblastoma cells, may prove to be an appropriate target for therapies aimed at treating these brain tumors, according to a study led by researchers in the Duke Department of Anesthesiology and the Preston Robert Tisch Brain Tumor Center at Duke.

"There are some previously identified cellular targets for therapy which are now being investigated in clinical trials, and the findings from our research represent potential alternate or complementary targets that may help patients facing this devastating disease," said Madan Kwatra, PhD, a researcher in Duke's department of anesthesiology, and senior investigator on this study. "Patients generally die from the disease within 18 months of glioblastoma diagnosis."

The results of the study were published in the March 30, 2009 online edition of the Journal of Neurochemistry. The study was funded by the National Institutes of Health.

The researchers examined stimulation of the receptor NK1R in human glioblastoma cells growing in a dish, and found that activation of NK1R led to the activation of Akt, a cellular protein that suppresses the natural cell death process.

"In human cancers, this would translate into a proliferation of cancer cell growth," said Kwatra.

The researchers also showed that blocking NK1R activity reduced Akt activity, which then led to greater cell death.

"This finding suggests that if we are able to block NK1R activity, we may have a better shot at stalling cancer growth," Kwatra said.

A previous study showed NK1R activity in 10 out of 10 glioblastomas and nine out of 12 astrocytomas, a lower-grade malignant brain tumor.

Current thera
'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Herpes: Scientists find cellular process that fights virus
2. Liver cell adenoma or hepatocellular carcinoma?
3. American TeleCare to Present its Wireless Wide Area Network (WWAN) Option for Cellular Telehealth Connectivity at the American Telemedicine Association (ATA) Annual Meeting
4. Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
5. CompuCyte Corporation and Program in Cellular and Molecular Medicine at Childrens Hospital Boston Announce Joint Program for Quantitative Imaging Cytometry Research Services
6. Enhanced skin cancer risk linked to defects in cellular aging controls
7. Team learns how cellular protein detects viruses and sparks immune response
8. U.S. Cellular President and CEO to Give Keynote at Employment Expo
9. Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration
10. CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy
11. Dormant cancer cells rely on cellular self-cannibalization to survive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 ... of “Women’s Health,” a campaign that seeks to educate, ... role when it comes to their health and their ... the rise, it has never been more pertinent to ... rights. , The print component of “Women’s Health” ...
(Date:3/6/2015)... March 06, 2015 “ Pokemini ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... , Over the last couple of years, mobile games ... the game. For example, Candy Crush allows users to connect ...
(Date:3/6/2015)... Ticket Down is a reputable source for ... the Moda Center. After being away from the touring ... no signs of letting up on his “Garth Brooks World ... wife, Trisha Yearwood, to venues around the United States. The ... acclaimed tour to the Moda Center in Portland, OR. The ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues ... organization has hired two new Scientific Program Officers, Amanda ... report to Grace Pavlath, Ph.D, who joined MDA late ... Director, and together will lead MDA as it accelerates ... for various types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 US Sports ... three Maryland camps – two non-contact specialty camps and ... run by Perfect Performance Training, located at Bowie State ... on developing position specific skills, speed and strength of ... at Salisbury University with Marvin Graves, former quarterback in ...
Breaking Medicine News(10 mins):Health News:The Well-Woman: Encouraging Regular Screenings and Advocating for Women’s Health Rights with Mediaplanet’s “Women’s Health” Campaign 2Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2
... of genetics, environment caused mice to develop disease, study finds ... with mice, scientists have found a bacteria living in the ... rheumatoid arthritis. , The gut of all mammals is populated ... are essential for developing a normal immune system. But some ...
... Announcing a new Web ... to improve the look and strength of your abdominal muscles and improve overall health. Get ... site. , ... A new Web site has been developed to help anyone get in shape. If you ...
... ... to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, ... ... is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA ...
... ... Guidance Based on Experience at Pfizer, Merck, Medtronic, GTx, Johnson & Johnson, and the University ... ... 2010 -- To support its focus on regulatory compliance in the life sciences, openQ has ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is an uncommon benign neoplasm with locally aggressive behavior but ... a 14-year-old patient with clinical presentations of abdominal pain and ... research article to be published on June 7, 2010 in ... A research team led by Professor Ko from Chang Gung ...
Cached Medicine News:Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 2Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 3Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:openQ Announces the Formation of a Compliance Advisory Board 2Health News:openQ Announces the Formation of a Compliance Advisory Board 3
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical Companies, ... conference call on Friday, March 13, 2015 at ... operations for the fourth quarter and full year ... and currently makes certain financial information available to ... and Exchange Commission and will make certain other ...
(Date:3/6/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... milestone payment from Biogen Idec related to advancing the ... in infants with spinal muscular atrophy (SMA).  ... is a randomized, double-blind, sham-procedure controlled thirteen month ... study will evaluate the efficacy and safety of a ...
(Date:3/5/2015)... March 5, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the pharmaceutical, biotechnology, ... the United States, today announced its financial results for ... Fourth-Quarter 2014 Highlights , Net Revenues Increased ... Laboratory Services Net Revenues Grew 17.7% Year Over Year ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... presented at the 2008 iSBTc Annual Meeting -, ... a.m. ET to discuss,results -, BRANFORD, Conn., Nov. ... preliminary data from an ongoing Phase II,trial of CR011-vcMMAE, ... patients with unresectable Stage III or Stage IV melanoma.,Dr. ...
... Clinical Study of Paliperidone ER in this Under-Studied ... with schizoaffective,disorder receiving paliperidone extended release tablets (paliperidone ... their symptoms, according,to a new study presented today ... San Diego, Calif.(1) In addition, safety findings were ...
Cached Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6
... step in the evolution of the ... to use, easy to learn ETT ... standard tube, as well as a ... handle intubations of difficult airways, without ...
Indications For Usage: ,Facilitates intubation of tracheal tubes....
Indications For Usage: ,Microlaryngeal surgery....
... the early onset of VAP. (Valles J, ... aspiration of subglottic secretions in preventing ventilator-associated ... Mahul P, Auboyer C, Jospe R, et ... patients: respective role of mechanical subglottic secretions ...
Medicine Products: